The chart is not accessible to screen readers. Please switch to the table view to access the data.
Advertisement
Advertisement
Percentage return on investments in research and development among mid cap biopharma companies from 2013 to 2020
Percentage return on R&D among mid cap biopharma companies 2013-2020
This statistic shows the percentage of return on investments in research and development among mid cap biopharmaceutical companies from 2013 to 2020. Within this time period, the returns declined from 17.4 percent to 5.2 percent in 2019. In 2020. returns increased slightly to 6.6 percent.
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Other statistics that may interest you Statistics on
About the industry
10
- Premium Statistic Percentage return on R&D among large cap biopharma companies 2010-2020
- Basic Statistic 3 year average R&D cost to develop new biopharmaceutical compounds 2010-2020
- Basic Statistic R&D cost to develop new pharmaceutical compounds 2010-2020
- Premium Statistic Cost to bring large cap biopharmaceutical assets to market 2010-2020
- Basic Statistic Number of biopharma venture financing deals 2017-2022
- Premium Statistic Total number of pharma merger and acquisition deals 2020-2024
- Premium Statistic Value of pharma and biotech merger and acquisition deals 2020-2024
- Basic Statistic Biopharmaceutical industry impact on labor income U.S. 2022
- Basic Statistic Projection of top therapeutic areas by sales worldwide 2019
- Basic Statistic Impact of U.S. biopharmaceutical industry on employment 2022
About the region
10
- Premium Statistic Orphan vs. non-orphan drugs median cost per patient per year 2014-2018
- Basic Statistic Top global orphan drugs by revenue 2018
- Basic Statistic Worldwide Rx drug sales excluding generics and orphan drugs 2012-2026
- Basic Statistic Orphan drug sales worldwide by therapy category 2030
- Basic Statistic Number of acquisition deals in biopharma industry 2017-2021, by therapy focus
- Premium Statistic Revenue forecast for global biologics market 2016-2022
- Premium Statistic Top 10 global pharmaceutical companies by revenue 2025
- Premium Statistic Market cap of select pharma companies with strong pipeline 2017
- Basic Statistic Number of startups using AI in drug discovery worldwide 2019, by area of discovery
- Basic Statistic Total value of private biopharma M&A deals worldwide 2008-2012
Selected statistics
10
- Premium Statistic Average peak sales forecast per new biopharmaceutical asset 2013-2025
- Premium Statistic Average R&D cost to develop new biopharma compound 2013-2025
- Premium Statistic Members of EFPIA's pharmaceutical R&D spending 1990-2025
- Basic Statistic Projected top pharmaceutical companies based on sales 2023
- Premium Statistic R&D spending growth worldwide on pharmaceuticals 2019-2032
- Basic Statistic Projected top pharmaceutical companies based on new sales 2023
- Premium Statistic Growth rate of R&D spending in pharmaceutical industry by major region 2010-2024
- Premium Statistic Number of biopharma M&A deals worldwide 2010-2019, by companies
- Premium Statistic Top U.S. pharmaceutical patent expiries by revenue 2014-2016
- Basic Statistic Number of biopharma M&A deals worldwide 2010-2019, by total transaction value
Other regions
10
- Premium Statistic Biopharmaceutical market size forecast Japan 2011-2020
- Premium Statistic Annual average cost of orphan drugs per patient 2014-2018
- Basic Statistic Biopharmaceutical industry impact on output U.S. 2022
- Basic Statistic Pharmaceutical businesses: R&D employment in the United Kingdom (UK) 2019, by type
- Basic Statistic U.S. and Europe biopharma company trade sales 2009 to 2019
- Basic Statistic Biopharmaceutical industry impact on added value U.S. 2022
- Basic Statistic YTD stock performance of biopharma companies working on COVID March 2020
- Premium Statistic Market share of generics in Finland 2016-2021
- Basic Statistic U.S. venture investments in infectious disease companies 2006-2023
- Premium Statistic U.S. pharma industry R&D expenditure 1980-2024
Related statistics
10
- Basic Statistic Combined value of biopharma takeout deals worldwide 2017-2021, by therapy focus
- Premium Statistic Members of EFPIA's pharmaceutical market value 2000-2025
- Basic Statistic Members of EFPIA's pharmaceutical exports and imports 1990-2025
- Basic Statistic Revenue forecast of CRO market 2016-2021, by location
- Premium Statistic Leading pharmaceutical companies' SG&A to revenue rate 2024
- Premium Statistic Global pharmaceutical market revenue 2015 vs. 2020, by world region
- Basic Statistic Employees at Sobi 2013-2024
- Basic Statistic Alzheimer's drugs in development in 2019, by clinical trial phase
- Basic Statistic Change in global biotech-pharma industry stock indices 2019
- Premium Statistic Leading global pharmaceutical risers based on share price 2022
Further Content: You might find this interesting as well
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Deloitte. (May 24, 2021). Percentage return on investments in research and development among mid cap biopharma companies from 2013 to 2020 [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 25, 2026, from /statistics/825714/randd-returns-among-mid-cap-biopharma-companies/
Deloitte. "Percentage return on investments in research and development among mid cap biopharma companies from 2013 to 2020." Chart. May 24, 2021. ÌÇÐÄÆƽâ°æ. Accessed July 25, 2026. /statistics/825714/randd-returns-among-mid-cap-biopharma-companies/
Deloitte. (2021). Percentage return on investments in research and development among mid cap biopharma companies from 2013 to 2020. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 25, 2026. /statistics/825714/randd-returns-among-mid-cap-biopharma-companies/
Deloitte. "Percentage Return on Investments in Research and Development among mid Cap Biopharma Companies from 2013 to 2020." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 24 May 2021, /statistics/825714/randd-returns-among-mid-cap-biopharma-companies/
Deloitte, Percentage return on investments in research and development among mid cap biopharma companies from 2013 to 2020 ÌÇÐÄÆƽâ°æ, /statistics/825714/randd-returns-among-mid-cap-biopharma-companies/ (last visited July 25, 2026)
Percentage return on investments in research and development among mid cap biopharma companies from 2013 to 2020 [Graph], Deloitte, May 24, 2021. [Online]. Available: /statistics/825714/randd-returns-among-mid-cap-biopharma-companies/
Advertisement